Health Economics

Economic analysis allows healthcare decision makers to make resource allocation decisions, by performing cost-benefit analysis of the various interventions. Such analyses are important in the area of pharmacogenomics. It is expected that pharmacogenomics is most likely cost-effective, since it reduces the incidence of adverse drug reactions, which can reciprocally reduce healthcare expenditure at the national level.

This working group is currently evaluating the impact of pharmacogenomic testing in reducing the healthcare costs of anticoagulation therapy and treatment for nicotine addiction, while these projects will soon be expanded in various healthcare systems to assess whether pharmacogenomics can indeed reduce the overall costs of these treatment modalities.

Home Working Groups Economic Evaluation in Genomic Medicine

You can find us

1

145 -157 St John Street, London, EC1V 4PW, UK

Tel: +44-(0)207-608.51.91,
E-mail: gma(AT)goldenhelix{DOT}org